Calidi Biotherapeutics Overview

  • Year Founded
  • 2014

Year Founded

  • Status
  • Public

  • Employees
  • 29

Employees

  • Stock Symbol
  • CLDI

Stock Symbol

  • Investments
  • 1

  • Share Price
  • $0.51
  • (As of Thursday Closing)

Calidi Biotherapeutics General Information

Description

Calidi Biotherapeutics Inc is a biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease. The company's proprietary RedTail platform features an engineered enveloped oncolytic virus designed for systemic delivery and targeting of metastatic sites. Its technology is intended to shield the virus from immune clearance, allowing virotherapy to effectively reach tumor sites, induce tumor lysis, and deliver potent genetic medicine(s) to metastatic locations. Its product candidates include The RedTail for Metastatic Solid Tumors, CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-101 (NeuroNova) for Newly Diagnosed High Grade Glioma.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 4475 Executive Drive
  • Suite 200
  • San Diego, CA 92121
  • United States
+1 (858)
Primary Industry
Drug Discovery
Other Industries
Other Pharmaceuticals and Biotechnology
Biotechnology
Stock Exchange
ASE
Vertical(s)
Corporate Office
  • 4475 Executive Drive
  • Suite 200
  • San Diego, CA 92121
  • United States
+1 (858)

Calidi Biotherapeutics Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Calidi Biotherapeutics Stock Performance

As of 19-Nov-2026, Calidi Biotherapeutics’s stock price is $0.51. Its current market cap is $1.74M with 3.45M shares.

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.51 $0.53 $0.50 - $24.80 $1.74M 3.45M 101K -$0.76

Calidi Biotherapeutics Financials Summary

As of 30-Sep-2026, Calidi Biotherapeutics has a trailing 12-month revenue of null.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 1,805 1,599 29,284 53,151
Revenue 0 0 0 0
EBITDA (14,101) (18,190) (19,727) (26,875)
Net Income (15,970) (19,906) (22,143) (29,216)
Total Assets 5,523 8,857 14,182 10,019
Total Debt 1,024 2,564 7,036 7,236
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Calidi Biotherapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Calidi Biotherapeutics‘s full profile, request access.

Request a free trial

Calidi Biotherapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Calidi Biotherapeutics‘s full profile, request access.

Request a free trial

Calidi Biotherapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Calidi Biotherapeutics Inc is a biotechnology company pioneering the development of targeted therapies with the potentia
Drug Discovery
San Diego, CA
29 As of 2025

Woburn, MA
 

Boston, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Calidi Biotherapeutics Competitors (3)

One of Calidi Biotherapeutics’s 3 competitors is Minerva Biotechnologies, a Venture Capital-Backed company based in Woburn, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Minerva Biotechnologies Venture Capital-Backed Woburn, MA
Vor Biopharma Formerly VC-backed Boston, MA
BioEclipse Therapeutics Venture Capital-Backed Mountain View, CA
You’re viewing 3 of 3 competitors. Get the full list »

Calidi Biotherapeutics Patents

Calidi Biotherapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
JP-7329593-B2 An enhanced system for cell-mediated oncolytic virus therapy Active 06-Nov-2018
JP-2022520298-A Enhanced system for the treatment of cell-mediated oncolytic viruses Active 06-Nov-2018
JP-2023166382-A Enhanced systems for cell-mediated oncolytic viral therapy Active 06-Nov-2018
WO-2020097269-A1 Enhanced systems for cell-mediated oncolytic viral therapy Inactive 06-Nov-2018
JP-2021531737-A Cell-based medium for enhancing viral therapy Active 04-Jun-2018 C12N5/0667
To view Calidi Biotherapeutics’s complete patent history, request access »

Calidi Biotherapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Calidi Biotherapeutics Acquisitions (1)

Calidi Biotherapeutics’s most recent deal was a Merger/Acquisition with First Light Acquisition Group. The deal was made on 12-Sep-2023.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
First Light Acquisition Group 12-Sep-2023 Merger/Acquisition Special Purpose Acquisition Company (SPAC)
To view Calidi Biotherapeutics’s complete acquisitions history, request access »

Calidi Biotherapeutics ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Biotechnology

Subindustry

Rank

Percentile

To view Calidi Biotherapeutics’s complete esg history, request access »

Calidi Biotherapeutics FAQs

  • When was Calidi Biotherapeutics founded?

    Calidi Biotherapeutics was founded in 2014.

  • Where is Calidi Biotherapeutics headquartered?

    Calidi Biotherapeutics is headquartered in San Diego, CA.

  • What is the size of Calidi Biotherapeutics?

    Calidi Biotherapeutics has 29 total employees.

  • What industry is Calidi Biotherapeutics in?

    Calidi Biotherapeutics’s primary industry is Drug Discovery.

  • Is Calidi Biotherapeutics a private or public company?

    Calidi Biotherapeutics is a Public company.

  • What is Calidi Biotherapeutics’s stock symbol?

    The ticker symbol for Calidi Biotherapeutics is CLDI.

  • What is the current stock price of Calidi Biotherapeutics?

    As of 19-Nov-2026 the stock price of Calidi Biotherapeutics is $0.51.

  • What is the current market cap of Calidi Biotherapeutics?

    The current market capitalization of Calidi Biotherapeutics is $1.74M.

  • Who are Calidi Biotherapeutics’s competitors?

    Minerva Biotechnologies, Vor Biopharma, and BioEclipse Therapeutics are competitors of Calidi Biotherapeutics.

  • What is Calidi Biotherapeutics’s annual earnings per share (EPS)?

    Calidi Biotherapeutics’s EPS for 12 months was -$0.76.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process